<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03862430</url>
  </required_header>
  <id_info>
    <org_study_id>NVX-108-GBM-P2</org_study_id>
    <nct_id>NCT03862430</nct_id>
  </id_info>
  <brief_title>NVX-108 Combined With Radiation &amp; TMZ, and During Maintenance Phase for Newly-diagnosed Glioblastoma Multiforme</brief_title>
  <official_title>Ph II Double-blinded, Randomized, Prospective, Placebo-controlled Study of NVX-108 Combined With Radiation &amp; Temozolomide &amp; During Maintenance Phase in Association With Temozolomide in Patients With Newly-diagnosed Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuvOx LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NuvOx LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is testing the safety, tolerability and effectiveness of NVX-108&#xD;
      administered via intravenous infusion in combination with standard radiation and&#xD;
      chemotherapy.&#xD;
&#xD;
      NVX-108 is being developed to increase the amount of oxygen delivered to tumors which is&#xD;
      hoped to increase the effectiveness of radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>22 months</time_frame>
    <description>To determine progression free survival (PFS) in newly-diagnosed glioblastoma patients after treatment with NVX-108 in combination with radiation and temozolomide (TMZ)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>22 months</time_frame>
    <description>To determine overall survival (OS) in newly-diagnosed glioblastoma patients after treatment with NVX-108 at the RD in combination with radiation and temozolomide.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate to study therapy</measure>
    <time_frame>22 Months</time_frame>
    <description>To determine the objective response rate to study therapy using Response Assessment in Neuro-oncology (RANO) criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">87</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>NVX 108</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVX-108 infusion in conjunction with Radiation Treatment and temozolimide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Saline infusion in conjunction with Radiation Treatment and temozolimide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVX-108</intervention_name>
    <description>0.1 mL/kg (2% w/vol emulsion)</description>
    <arm_group_label>NVX 108</arm_group_label>
    <other_name>Dodecafluoropentane emulsion (DDFPe)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Saline Infusion</intervention_name>
    <description>0.1 mL/kg Saline Infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically-confirmed newly-diagnosed primary and secondary glioblastoma&#xD;
             multiforme.&#xD;
&#xD;
          2. No prior treatment for glioblastoma apart from surgical resection.&#xD;
&#xD;
          3. Planned for 60 Gy of focal radiation administered in 30 fractions, concurrently with&#xD;
             temozolomide chemotherapy.&#xD;
&#xD;
          4. Manageable risks associated with potential radiation necrosis in the radiation field,&#xD;
             based on size of the field and proximity to eloquent brain regions (as assessed by the&#xD;
             investigator).&#xD;
&#xD;
          5. Aged 18 years and older.&#xD;
&#xD;
          6. ECOG Performance Status 0-2.&#xD;
&#xD;
          7. Life expectancy of at least 3 months.&#xD;
&#xD;
          8. If receiving glucocorticoid therapy, the dose must be stable or decreasing over at&#xD;
             least 7 days prior to study enrolment.&#xD;
&#xD;
          9. Archived tumor tissue (10 slides per patient) available for central review.&#xD;
&#xD;
         10. Able to undergo gadolinium-enhanced MRI (Gd-MRI) scans.&#xD;
&#xD;
         11. Baseline MRI performed within 28 days before starting study treatment, while on a&#xD;
             stable glucocorticoid dose for at least 7 days before and during the imaging study.&#xD;
&#xD;
         12. Adequate hematologic, renal and hepatic function, as defined by:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Platelet count ≥ 75 x 109/L&#xD;
&#xD;
               -  Hemoglobin ≥ 10.0 g/dl&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 x ULN&#xD;
&#xD;
               -  Total bilirubin within normal limits (≤ 2.5 x ULN if Gilbert's syndrome)&#xD;
&#xD;
               -  Aspartate transaminase (AST) and Alanine transaminase (ALT) &lt; 3 x ULN&#xD;
&#xD;
         13. Women of childbearing potential or men with child-bearing potential partners (unless&#xD;
             vasectomized) must agree to use a highly-effective method of birth control from study&#xD;
             entry until 4 months after completing study therapy. Should a study participant or&#xD;
             their partner become pregnant or suspect a pregnancy they should inform the treating&#xD;
             physician immediately.&#xD;
&#xD;
         14. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recurrent Glioblastoma&#xD;
&#xD;
          2. Presence of multifocal glioblastoma&#xD;
&#xD;
          3. Presence of leptomeningeal disease that cannot be encompassed within a feasible and&#xD;
             safe radiation field.&#xD;
&#xD;
          4. Intracranial bleeding, except for stable grade 1 hemorrhage or a post-operative bleed&#xD;
             that is clearing.&#xD;
&#xD;
          5. Has not recovered from the adverse effects of surgical resection or biopsy, except for&#xD;
             neurological deficits.&#xD;
&#xD;
          6. Subjects who have received any other investigational agent for the treatment of GBM&#xD;
             within 4 weeks before enrollment (Phase 0 compounds - e.g. microdoses of dye or drug&#xD;
             are eligible).&#xD;
&#xD;
          7. Stroke or transient ischemic attack requiring hospitalization within 6 months before&#xD;
             enrollment.&#xD;
&#xD;
          8. Myocardial infarction (MI) within 6 months before enrolment, unstable angina, New York&#xD;
             Heart Association (NYHA) class II or greater congestive heart failure, or uncontrolled&#xD;
             hypertension (systolic BP &gt; 160 mmHg and/or diastolic BP &gt; 100 mmHg).&#xD;
&#xD;
          9. Known History of Congenital long QT syndrome (12-lead EKG is not required).&#xD;
&#xD;
         10. Clinically-significant chronic obstructive pulmonary disease or asthma.&#xD;
&#xD;
         11. Active major infection requiring treatment.&#xD;
&#xD;
         12. A history of other malignancies, except adequately treated non-melanoma skin cancer,&#xD;
             curatively treated in-situ cancers or other solid tumors curatively treated with no&#xD;
             evidence of disease for ≥ 2 years.&#xD;
&#xD;
         13. Known infection with human immunodeficiency virus or hepatitis B or C virus (testing&#xD;
             is not required).&#xD;
&#xD;
         14. Current anticoagulant or antiplatelet therapy, except for prophylactic doses of low&#xD;
             molecular weight heparins, low-dose aspirin, rivaroxaban (Xarelto®), apixaban&#xD;
             (Eliquis®), or dabigatran (PRADAXA®).&#xD;
&#xD;
         15. History of allergic reactions attributed to compounds of similar chemical composition&#xD;
             to NVX-108.&#xD;
&#xD;
         16. Women who are pregnant or breast feeding.&#xD;
&#xD;
         17. Inability to comply with study procedures&#xD;
&#xD;
         18. History or evidence of any other clinically-significant condition that, in the opinion&#xD;
             of the investigator, would pose a risk to subject safety or interfere with study&#xD;
             procedures, evaluation or completion.&#xD;
&#xD;
         19. Known hypersensitivity to any temozolomide component or to dacarbazine (DTIC).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Evan Unger, MD</last_name>
    <phone>520-624-6688</phone>
    <email>eunger@nuvoxpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivia Longacre</last_name>
    <phone>520-624-6688</phone>
    <email>olongacre@nuvoxpharma.com</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

